Abstract
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an emerging curative treatment option for patients with peritoneal carcinomatosis. It has a long-term survival benefit but is associated with high rates of morbidity, ranging from 12% to 65%, mainly due to infectious complications. We sought to evaluate the clinical relevance of routine intraoperative bacteriological sampling following CRS/HIPEC. Between November 2010 and December 2014, every patients receiving CRS/HIPEC were included. Three samples were routinely collected from standardized locations for intraperitoneal rinsing liquid bacteriological analysis (RLBA) after completion of HIPEC. The clinical and surgical features, bacteriological results, and short-term outcomes were retrospectively reviewed. The overall mortality and morbidity rates were 5 and 45%, respectively. Among the 75 included patients, 40% (n=30) had at least one positive bacterial culture. Risk factors for a positive culture were colorectal resection (adjusted hazard ratio [HR]=3.072, 95% CI 1.843-8.004; p=0.009) and blood loss >1000mL (HR=4.272, 95% CI 1.080-18.141; p=0.031). Among 26 (35%) patients with abdominal infectious complications, 13 (17%) experienced isolated complications. A positive RLBA result was independently associated with abdominal infectious complications (HR=5.108, 95% CI 1.220-16.336; p=0.024) and isolated abdominal infectious complications (HR=4.199, 95% CI 1.064-15.961; p=0.04). Forty percent of the RLBA samples obtained following CRS/HIPEC tested positive for bacteria. Bacterial sampling of rinsing liquid should be systematically performed. An aggressive and immediate antibiotic strategy needs to be evaluated.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call